Your browser doesn't support javascript.
loading
Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.
Ambrogio, Chiara; Carmona, Francisco J; Vidal, August; Falcone, Mattia; Nieto, Patricia; Romero, Octavio A; Puertas, Sara; Vizoso, Miguel; Nadal, Ernest; Poggio, Teresa; Sánchez-Céspedes, Montserrat; Esteller, Manel; Mulero, Francisca; Voena, Claudia; Chiarle, Roberto; Barbacid, Mariano; Santamaría, David; Villanueva, Alberto.
Afiliação
  • Ambrogio C; Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Carmona FJ; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Vidal A; Department of Pathology, Hospital Universitari de Bellvitge, Barcelona, Spain.
  • Falcone M; Department of Genetics, Biology and Biochemistry, Molecular Biotechnology Center, University of Torino, Torino, Italy.
  • Nieto P; Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Romero OA; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Puertas S; Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Vizoso M; Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Nadal E; Department of Medical Oncology, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Poggio T; Department of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies (CERMS), University of Torino, Torino, Italy.
  • Sánchez-Céspedes M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Esteller M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona,
  • Mulero F; Molecular Imaging Unit, Biotechnology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Voena C; Department of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies (CERMS), University of Torino, Torino, Italy.
  • Chiarle R; Department of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies (CERMS), University of Torino, Torino, Italy. Department of Pathology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts.
  • Barbacid M; Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Santamaría D; Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. dsantamaria@cnio.es avillanueva@iconcologia.net.
  • Villanueva A; Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. XenOPAT S.L., Business Bioincubator, Bellvitge Health Science Campus, Barcelona, Spain. dsantamaria@cnio.es avillanueva@iconcologia.net.
Cancer Res ; 74(21): 5978-88, 2014 Nov 01.
Article em En | MEDLINE | ID: mdl-25217522
Cancer evolution is a process that is still poorly understood because of the lack of versatile in vivo longitudinal studies. By generating murine non-small cell lung cancer (NSCLC) orthoallobanks and paired primary cell lines, we provide a detailed description of an in vivo, time-dependent cancer malignization process. We identify the acquisition of metastatic dissemination potential, the selection of co-driver mutations, and the appearance of naturally occurring intratumor heterogeneity, thus recapitulating the stochastic nature of human cancer development. This approach combines the robustness of genetically engineered cancer models with the flexibility of allograft methodology. We have applied this tool for the preclinical evaluation of therapeutic approaches. This system can be implemented to improve the design of future treatments for patients with NSCLC.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Evolução Biológica / Neoplasias Pulmonares / Neoplasias Experimentais Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Evolução Biológica / Neoplasias Pulmonares / Neoplasias Experimentais Idioma: En Ano de publicação: 2014 Tipo de documento: Article